SCHEMBL3790085

SCHEMBL3790085

CCCOc1ccccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 8/20 0.59
MAPT P10636 4/20 0.58
TDP1 Q9NUW8 1/20 0.58
RAB9A P51151 6/20 0.57
NPC1 O15118 5/20 0.57
KCNH2 Q12809 1/20 0.54
CSNK2A1 P68400 2/20 0.53
MEN1 O00255 1/20 0.53
PKM P14618 1/20 0.53
KMT2A Q03164 1/20 0.53
HPGD P15428 2/20 0.53
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
TSHR P16473 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27524671 0.98 L3MBTL1 (0.58) L3MBTL1MAPTTDP1RAB9ANPC1
Dimethylamine SCHEMBL4367220 0.94 NPC1 (0.56) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL30167630 0.89 L3MBTL1 (0.66) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL3794754 0.89 L3MBTL1 (0.66) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL11874439 0.88 L3MBTL1 (0.64) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL9808263 0.86 L3MBTL1 (0.68) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL11662071 0.86 L3MBTL1 (0.62) L3MBTL1MAPTTDP1RAB9ANPC1
1,2-Dipropoxybenzene SCHEMBL29428926 0.84 CYP1A2 (0.56) L3MBTL1MAPTTDP1RAB9ANPC1
1,2-Dipropoxybenzene SCHEMBL578657 0.84 CYP1A2 (0.56) L3MBTL1MAPTTDP1RAB9ANPC1
SCHEMBL15473216 0.83 ALDH1A1 (0.54) L3MBTL1TDP1RAB9ANPC1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169209-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2015-10-27 US claimed
US-20140275057-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2014-09-18 US claimed
WO-2012150952-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA TM, LLC (US) 2012-11-08 WO claimed
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2022-03-22 US disclosed
EP-3233799-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2021-05-19 EP disclosed
US-9994558-B2 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. (US) 2018-06-12 US disclosed
US-9707205-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2017-07-18 US disclosed
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. (US) 2017-04-06 US disclosed
WO-2012150952-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA TM, LLC (US) 2012-11-08 WO disclosed
CN-102361837-A Process for producing conjugated aromatic compound SUMITOMO CHEMICAL CO 2012-02-22 CN disclosed
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2010-11-18 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ARTESIAN THERAPEUTICS, INC. (CA) 2008-10-23 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
WO-2001056358-A2 ENHANCED PROPERTIED PESTICIDES ROHM AND HAAS COMPANY (US) 2001-08-09 WO disclosed
EP-0234045-A2 A pyrazole oxime derivative and its production and use NIHON NOHYAKU CO., LTD. (JP) 1987-09-02 EP disclosed
US-4542243-A HALOALKYLATION, ETHERIFICATION, HYDRODEHALOGENATION, INSECTICIDES MITSUI TOATSU CHEMICALS, INC. (JP) 1985-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 L3MBTL1 3643/4885MAPT 694/4885TDP1 4076/4885
US-20170096417-A1 Multicyclic Compounds And Methods Of Using Same PAK4, PAK5, PAK1 L3MBTL1 4300/4885MAPT 1510/4885TDP1 3687/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT L3MBTL1 3102/4885MAPT 256/4885TDP1 3705/4885
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ADRB2, ADRB3, ADRB1 L3MBTL1 3584/4885MAPT 4285/4885TDP1 1223/4885
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 L3MBTL1 2990/4885MAPT 268/4885TDP1 3665/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 L3MBTL1 3838/4885MAPT 3312/4885TDP1 4196/4885
US-20140275057-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NAPRT L3MBTL1 3184/4885MAPT 422/4885TDP1 3639/4885
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES GPR119, CPT1A, GLS2 L3MBTL1 4242/4885MAPT 3155/4885TDP1 4666/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 L3MBTL1 3563/4885MAPT 519/4885TDP1 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.